PMID- 21410079
OWN - NLM
STAT- MEDLINE
DCOM- 20110413
LR  - 20220410
IS  - 0172-6390 (Print)
IS  - 0172-6390 (Linking)
VI  - 57
IP  - 102-103
DP  - 2010 Sep-Oct
TI  - The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 
      3rd rescue regimen for eradication of H. pylori.
PG  - 1314-9
AB  - BACKGROUNDS/AIMS: Most of patients who are refractory to usual standard 
      eradication therapies for H. pylori infection have rapid metabolizer genotype of 
      CYP2C19 and are infected with resistant strains to several antimicrobial agents. 
      However, most of H. pylori strains are sensitive to amoxicillin. We tested 
      whether dual therapy with the 4 times daily dosing of rabeprazole and amoxicillin 
      was effective as the 3rd rescue regimen for eradication of H. pylori. 
      METHODOLOGY: 49 patients who failed in eradication of H. pylori after two (1st: 
      proton pump inhibitor (PPI)/amoxicillin/clarithromycin and 2nd: 
      PPI/amoxicillin/metronidazole) were enrolled to the study. They were treated with 
      rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. for 2 weeks. At 4 weeks 
      after the treatment, they underwent the [13C]-urea breath test. When the result 
      of [13C]-urea breath test was negative, they underwent the endoscopy and the 
      successful eradication was confirmed by rapid urease test. RESULTS: All patients 
      completed the treatment. The eradication rate was 87.8% (43/49) (95% CI = 
      75.2%-95.4%). No undesirable severe adverse events were observed during the study 
      period. CONCLUSIONS: The dual therapy with 4 times daily dosing of rabeprazole 
      and amoxicillin is well tolerated and effective as the 3rd rescue regimen for 
      eradication of H. pylori.
FAU - Furuta, Takahisa
AU  - Furuta T
AD  - Center for Clinical Research, Hamamatsu University School of Medicine 1-20-1, 
      Handayama, Higashi-Ku, Hamamatsu 431-3192, Japan. furuta@hama-med.ac.jp
FAU - Sugimoto, Mitsushige
AU  - Sugimoto M
FAU - Kodaira, Chise
AU  - Kodaira C
FAU - Nishino, Masafumi
AU  - Nishino M
FAU - Yamade, Mihoko
AU  - Yamade M
FAU - Uotani, Takahiro
AU  - Uotani T
FAU - Ikuma, Mutsuhiro
AU  - Ikuma M
FAU - Shirai, Naohito
AU  - Shirai N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Hepatogastroenterology
JT  - Hepato-gastroenterology
JID - 8007849
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 32828355LL (Rabeprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*administration & dosage
MH  - Aged
MH  - Amoxicillin/*administration & dosage
MH  - Aryl Hydrocarbon Hydroxylases/genetics
MH  - Cytochrome P-450 CYP2C19
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Helicobacter Infections/*drug therapy
MH  - *Helicobacter pylori/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Rabeprazole
EDAT- 2011/03/18 06:00
MHDA- 2011/04/14 06:00
CRDT- 2011/03/18 06:00
PHST- 2011/03/18 06:00 [entrez]
PHST- 2011/03/18 06:00 [pubmed]
PHST- 2011/04/14 06:00 [medline]
PST - ppublish
SO  - Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1314-9.